



# HHS Public Access

Author manuscript

*Neurobiol Sleep Circadian Rhythms*. Author manuscript; available in PMC 2018 January 01.

Published in final edited form as:

*Neurobiol Sleep Circadian Rhythms*. 2017 January ; 2: 53–58. doi:10.1016/j.nbscr.2016.11.001.

## Circadian Dysregulation in Parkinson's Disease

**Aleksandar Videnovic, MD, MSc, FAAN, FAASM** and

Movement Disorders Unit and Division of Sleep Medicine, Massachusetts General Hospital, Harvard Medical School, MGH Neurological Clinical Research Institute, 165 Cambridge Street, Suite 600, Boston, MA 02446, phone: 617.724.3837, fax: 617. 643.3558

**Diego Golombek, PhD**

Department of Science and Technology, National University of Quilmes/CONICET, R.S. Peña 352, (1876) Bernal, Buenos Aires, Argentina, phone: +54-11-43657100 ext 5626, fax: +54-11-4365-7132

### Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder that affects over one million individuals in the US alone. PD is characterized by a plethora of motor and non-motor manifestations, resulting from a progressive degeneration of dopaminergic neurons and disbalance of several other neurotransmitters. A growing body of evidence points to significant alterations of the circadian system in PD. This is not surprising given the pivotal role that dopamine plays in circadian regulation as well as the role of circadian influences in dopamine metabolism. In this review we present basic and clinical investigations that examined the function of the circadian system in PD.

### Keywords

Parkinson's; circadian; sleep; dopamine; clock genes

## 1. Introduction

Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting over one million people in the United States (Dorsey, Constantinescu et al. 2007, Alves, Forsaa et al. 2008). Motor hallmarks required to establish the diagnosis of PD include tremor, bradykinesia, and rigidity. These symptoms emerge due to progressive dopaminergic loss within the nigro-striatal system. Non-motor manifestations of PD are common and represent some of the most disabling dopa-resistant symptoms of PD. These symptoms encompass sleep disturbances, autonomic dysfunction, mood and psychiatric disturbances, and reflect ongoing neurodegeneration outside the basal ganglia systems. Both motor and non-motor manifestations of PD demonstrate strong diurnal oscillations (Dotto et al. 2000,

Correspondence to: Aleksandar Videnovic.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Pathak and Senard 2006, Davies et al. 2008, Piccini, Del Dotto et al. 1991). This raises a possibility that the circadian system drives some changes of biological rhythms in PD. Circadian dysregulation has indeed emerged as an important etiology of sleep disruption in the most common neurodegenerative disorders, including PD, Huntington's (HD) and Alzheimer's (AD) diseases (Videnovic et al. 2014). Of note, circadian and sleep misalignment likely influence the neurodegenerative process itself (Mamelak 1997, Morton, Wood et al. 2005, Ju, Lucey et al. 2014). A good example of bidirectional relationship between sleep/circadian function and neurodegeneration is AD, where amyloid accumulation disrupts sleep and disrupted sleep increases the risk of accumulation of amyloid and development of dementia (Ju, Lucey et al. 2014). The role of the circadian system in PD has not been systematically studied to date. In this manuscript we review the current understanding of circadian function in experimental models of PD and in the clinical expression of this disorder.

## 2. Dopamine and circadian system

Since dopaminergic neurotransmission lies at the core of PD-related disorders, it is relevant to acknowledge diurnal and circadian variation in dopamine content and metabolism. Indeed, diurnal variation in dopamine and some of its metabolites has been reported for many years (Kafka, Benedito et al. 1986). Changes in dopamine content could be directly related to rhythms in its synthesizing enzymes (tyrosine hydroxylase (TH)) and transporters (DAT), whose activity exhibit temporal changes both in basal ganglia and cortical structures (Sleipness, Sorg et al. 2007). Indeed, rhythmic dopaminergic activity can be controlled by the circadian clock and, in turn, might also regulate the activity of the clock itself (Sleipness, Sorg et al. 2007, Mendoza and Challet 2014). In addition, dopamine might be relevant in the modulation of circadian retinal input (Witkovsky 2004), and also as a developmental signal for the appearance of fetal and presumably neonatal rhythms (Seron-Ferre, Torres-Farfan et al. 2001).

We have recently reported that striatal dopamine levels exhibit daily rhythms with nocturnal peaks in mice (Agostino, do Nascimento et al. 2011), as had been previously demonstrated in rats (Castaneda, de Prado et al. 2004, Hood, Cassidy et al. 2010). Moreover, functional arrhythmocytia induced by bright constant light (Bussi, Levin et al. 2014) or SCN lesions (Sleipness, Sorg et al. 2007) disrupted dopamine and TH rhythms and reward-related behaviors such as interval timing. Clock genes also exhibit periodic variations in striatal structures (Li, Liu et al. 2009, Bussi, Levin et al. 2014, Natsubori, Honma et al. 2014), and could be related to rhythms in the expression of dopamine-related genes (Shumay, Fowler et al. 2012). Dopamine type 3 receptors also show 24-h fluctuations which are regulated by the canonical molecular clock (Ikeda, Matsunaga et al. 2013).

Indeed, circadian rhythms in dopaminergic function could be the molecular correlate of cycles in reward, motivation and/or timing behavior (reviewed in (Agostino, Golombek et al. 2011, Golombek, Bussi et al. 2014, Parekh, Ozburn et al. 2015)). Dopamine along with iron metabolism also seem to underlie circadian fluctuations in symptoms associated with restless legs syndrome, a movement disorder of sleep frequently associated with PD (Baier, Trenkwalder et al. 2007).

Dopaminergic influence has been implied at several levels within the circadian system. In retina, dopamine is involved in light adaptation and rhythmic expression of melanopsin and clock genes. Dopamine also modulates light input to the SCN from retina (Witkovsky 2004). While clock genes regulate dopaminergic transmission in the ventral tegmental area, dopamine regulates clock gene expression in the dorsal striatum (Roybal, Theobald et al. 2007, Hood, Cassidy et al. 2010). Dopaminergic activity can also be considered an output of the SCN. In summary, dopamine exhibits a two-way interaction with the circadian system at several levels.

### 3. Circadian system in PD – lessons from animal models

PD-related animal models have advanced our understanding of the disease process overall, and opened possibilities for exploring novel treatments and insight in the molecular and physiological mechanisms underlying PD-specific neurodegeneration. Studies that centered on alterations of circadian rhythmicity and applications of potential circadian-based interventions in animal models of PD are scarce. While non-specific, age-related circadian disruption has been reported in different PD animal models, especially rodents (Brown, Schmitt et al. 2011, Mattis and Sehgal 2016), these studies did not necessarily offer specific insights into the origin and scope of PD effects on biological rhythms and vice versa.

Most animal models of PD have been developed in rodents and centered on deficits in dopaminergic neurotransmission (Jagmag, Tripathi et al. 2015). In addition, non-human primates have provided an adequate model for testing potential therapeutic agents (Johnston and Fox 2015). The most widely used models are uni- or bilateral striatal administration of 6-hydroxydopamine (6-OHDA), which mimics some of the motor dysfunctions of the disease, as well as injection of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The latter induces motor symptoms accompanied by a specific loss of dopaminergic neurons (Burns, Chiueh et al. 1983). Another approach involves genetic manipulation of some of the key molecular regulators related to the development of PD (Crabtree and Zhang 2012). One of the main experimental paradigms within this group involves the over expression of  $\alpha$ -synuclein, the pathognomonic protein for PD-related neurodegeneration. In this model,  $\alpha$ -synuclein is over expressed under the control of a Thy- promoter and induces early motor and sensory deficits in mice (Kudo, Loh et al. 2011). In another model, mice with alterations in the expression of a key player of dopamine metabolism, the vesicular monoamine transporter 2 (VMAT-2), also show cellular and behavioral changes that resemble some of the clinical features of PD (Taylor, Caudle et al. 2009). Below we outline investigations that link sleep and circadian function with PD in animal models of this disorder.

#### 3.1. Circadian changes in animal models of PD

Non-motor symptoms in PD animal models have been studied extensively, including sleep changes (McDowell and Chesselet 2012). MPTP-treated primates exhibit significant disruption of the sleep-wake cycle (Vezoli, Fifel et al. 2011), in particular related to a deregulation of REM sleep. These changes are more severe compared to those found in the mouse model (Laloux, Derambure et al. 2008, Fifel, Piggins et al. 2016). A similar sleep

disruption has been described after MPTP administration in cats (Pungor, Papp et al. 1990). Further, MPTP-treated dogs exhibit blunted circadian oscillations in renal parameters, including urine volume, creatinine and several hormones (Hineno, Mizobuchi et al. 1992). Disruptive MPTP effects on sleep can be reversed by D1 receptor agonist administration (Hyacinthe, Barraud et al. 2014).

6-OHDA-treated rats exhibit severe sleep deficits, including significant circadian disruption (Gravota, Gavrilu et al. 2011). Indeed, bilateral lesions result in changes in the levels and oscillations of different circadian variables (Ben and Bruguierolle 2000). The 6-OHDA models exhibit disruptions in circadian rhythms of locomotion, temperature and heart rate, which are at least partially reversible by L-DOPA administration (Boulamery, Simon et al. 2010). It is interesting to note that optic enucleation increases the severity of PD-like symptoms in 6-OHDA lesioned rats, suggesting the importance of visual and circadian connections in PD (Willis 2008).

Circadian changes have been documented in rotenone-induced neurodegeneration in rats, including alterations in serotonergic transmission and circadian expression of clock genes; both parameters partially recover with melatonin administration (Mattam and Jagota 2015). Interactions between melatonin and dopamine are complex and not fully elucidated. While melatonin appears to have neuroprotective effects on the nigrostriatal dopaminergic system through its antioxidant properties and effects on mitochondrial activity, inhibition of dopamine release by melatonin in several brain areas has been demonstrated. It has been proposed that melatonin and dopamine may act as mutually inhibitory signals for night and day, respectively (Zisapel, 2001).

Circadian alterations have been reported in several other animal models of PD. Alterations in the glutamatergic transmission in the striatum also induce PD-like motor symptoms. The glutamate transporter 3 knockout mice exhibit diurnal hyperactivity and changes in circadian dopamine metabolism (Divito, Steece-Collier et al. 2015). Dopaminergic deficits induced by genetic deficiency of the vesicular monoamine transporter 2 (VMAT2) in mice are accompanied by a premature decrease in sleep latency and reduced amplitude of the sleep-wake cycle, as well as in dampened circadian rhythms in general (Taylor, Caudle et al. 2009).

$\alpha$ -synuclein transgenic mice exhibit fragmented rhythms of locomotor activity, as well as changes in firing rate in the suprachiasmatic nuclei (SCN), the site of the mammalian main circadian clock (Kudo, Loh et al. 2011). This fragmentation seems to be dependent on the photoperiodic conditions in which the animals were housed, and progresses with age. Adult transgenic mice exhibited diurnal wakefulness and increased hyperactivity pattern (McDowell, Shin et al. 2014). Another mouse model of PD involves inactivation of a mitochondrial transcription factor, MitoPark that induces dopaminergic degeneration. In this model deficits in locomotion and, more specifically, diurnal patterns of rest/activity were reported (Fifel and Cooper 2014).

It is important to note that the central circadian pacemaker, the SCN, also exhibits significant changes in animal models of PD. As indicated by Willison et al. (Fliers, Swaab et al. 1985),

oscillations in the suprachiasmatic nuclei are disrupted in  $\alpha$ -synuclein transgenic mice quite early in the development of the disease. An intriguing consequence of this observation is that circadian synchronization and treatments that increase circadian rhythm amplitude have to be explored further as these approaches may be beneficial for the management of PD.

Collectively, these basic investigations provide a support for alterations of circadian system in PD. Further studies that will employ carefully designed experiments will be needed to advance our understanding of the anatomical and pathophysiological signatures of circadian disruption associated with PD.

## 4. Clinical Implications of Circadian Function in PD

Circadian rhythms have not been systematically studied in PD patients. Despite this, available literature points to significant modifications of the circadian system in these patients. This is reasonable to expect, given a bi-directional relationship between dopamine metabolism and circadian system physiology. For example, the amplitude of the circadian rhythm of dopamine appears to be highest in the morning around 10am, and that of homovanillic acid in the afternoon, around 2pm (Poceta, Parsons et al. 2009). These circadian variations may underline sleep-related changes in function, readily observed by clinicians and reported by PD patients (Merrelo, Hughes, et al. 1997).

### 4.1. Diurnal clinical fluctuations in PD

Many symptoms and signs associated with PD demonstrate diurnal variations in its intensity and frequency. These symptoms are representative of multi system involvement in PD, and include fluctuations of motor function in PD (Nutt, Woodward et al. 1989, van Hilten, Middelkoop et al. 1991, van Hilten, Kabel et al. 1993, Bonuccelli, Del Dotto et al. 2000), autonomic and sensory functions (Pursiainen, Haapaniemi et al. 2002, Arias-Vera, Mansoor et al. 2003, Devos, Kroumova et al. 2003, Ejaz, Sekhon et al. 2006, Mihci, Kardelen et al. 2006, Pathak and Senard 2006), mood and cognitive performance (Suzuki, Miyamoto et al. 2007, Whitehead, Davies et al. 2008), and sleep and alertness (van Hilten, Weggeman et al. 1993, Comella 2007, Placidi, Izzi et al. 2008, Porter, Macfarlane et al. 2008, Verbaan, van Rooden et al. 2008). Observed variations may be influenced by circadian oscillations. Although the above discussed fluctuations in various variables may suggest an involvement of the circadian system, one must be cautious not to attribute the fluctuating nature of symptoms/signs of PD completely and directly to circadian disruption, since most studies to date did not employ rigorous circadian experimental protocol that would control for the effects of exogenous stimuli on the endogenous circadian rhythms and symptom manifestation in PD.

Studies that employed actigraphy in the PD population revealed flattening of the diurnal activity rhythms and reduced quiescence during night (Piccini, Del Dotto et al. 1991, Placidi, Izzi et al. 2008). This reduced amplitude of the rest-activity cycle is present in both de novo and more advanced patients, and appears to be independent of the intake of dopaminergic medications (Piccini, Del Dotto et al. 1991, van Hilten, Hoogland et al. 1993, van Hilten, Weggeman et al. 1993, van Hilten, Hoff et al. 1994, Placidi, Izzi et al. 2008). REM sleep behavior disorder (RBD) is a parasomnia frequently present in the PD

population, and characterized by motor and vocal behaviors that are disruptive to sleep and result in sleep fragmentation. While RBD itself may contribute to reduce quiescence during night, it is important to point out that RBD represents a sleep stage under the strong circadian influences that may be implicated in the pathophysiology of RBD. Similar to motor function, prominent changes in 24-hour rhythms of heart rate and blood pressure have been repeatedly reported in PD. These studies report reversal of the normal diurnal rhythm of BP with increased diurnal variability of BP and elevations of overnight BP along with loss of diurnal HR variability and a disappearance of the sympathetic morning peak (Mastrocola, Vanacore et al. 1999, Kallio, Haapaniemi et al. 2000, Haapaniemi, Pursiainen et al. 2001, Kallio, Suominen et al. 2004). Sensory systems, such as retinal function, also appear to be affected in PD. A good example of this is represented by diurnal changes in contrast sensitivity in PD patients, which may be modulated by circadian signaling of dopamine within the retinal tissues (Struck, Rodnitzky et al. 1990). Sleep and alertness are commonly disrupted in PD, and this frequently predates emergence of motor symptoms that are currently required to establish PD diagnosis. Sleep fragmentation represents the most common sleep problem in the PD population (Videnovic, Golombek 2013). The etiology of impaired sleep and alertness in PD is clearly multifactorial and encompasses PD symptoms, medications side effects, autonomic dysfunction, and co-existent primary sleep disorders (Videnovic and Golombek 2013). The role of circadian disruption has only recently started to emerge as an important etiology of impaired sleep and alertness in PD (Videnovic and Willis 2016).

Patients with PD frequently report “sleep benefit”, described as feeling well after awakening in the morning. They feel as they do not have PD, although they did not take their morning medications (Merrelo, Hughes, et al. 1997). The underlying mechanisms of sleep benefit have not been well-explored. The pattern of diurnal motor fluctuations and increased dopamine storage in nigral neurons during sleep with subsequent enhanced dopaminergic function have been implicated in sleep benefit (van Gilst, Bloem, et al. 2013, Factor, Weiner, 1998). In a study that assessed circadian influences on sleep benefit employing the Horne-Ostberg morningness-eveningness questionnaire, no differences in circadian phenotype were present between patients with and without sleep benefit (Hogl, Gomez-Arevalo, et al. 1998).

#### 4.2. Markers of the circadian system in PD

Endogenous circadian rhythms can be best characterized by analyzing circadian markers. Melatonin, cortisol and core body temperature are well established markers of endogenous circadian rhythmicity. These circadian markers have been increasingly investigated in PD. Specifically, circadian secretion of melatonin and its relationship with sleep dysfunction associated with PD has been recently examined in several studies. Phase angle of entrainment is defined as the relationship between the timing of the biological clock and the timing of an external time cue. Bolitho et al. demonstrated prolongation of the phase angle of entrainment of melatonin rhythm in the medicated PD patients compared to the PD unmedicated group and controls (Bolitho, Naismith et al. 2014). These observed changes in the phase angle provide the rationale to suggest uncoupling of circadian and sleep regulation, possibly related to dopaminergic therapy. Two other recent studies did not show

alterations in the circadian phase of melatonin secretion (Breen, Vuono et al. 2014, Videnovic, Noble et al. 2014). However, both studies reported decreased amplitude of melatonin secretion. The amplitude of melatonin circadian rhythm was significantly lower in patients with moderate PD compared with age-matched controls (Videnovic, Noble et al. 2014). Further, within the PD group, those with excessive daytime sleepiness had significantly lower amplitudes of their melatonin rhythm, compared to those with good alertness. This raises a question related to the role of circadian dysregulation in the pathophysiology of excessive sleepiness, frequently associated with PD. Breen and colleagues examined circadian profiles of melatonin, cortisol, and clock genes in a cohort of 30 patients with early PD and 15 matched controls (Breen, Vuono et al. 2014). PD patients had elevated cortisol levels and reduced melatonin levels. The significance of all these investigations in part lies in the fact that they employed rigorous circadian experimental designs that controlled well for exogenous signals known to affect endogenous circadian system such as light exposure, feeding schedules, ambient temperature, and physical activity. This is likely the primary reason underlying somewhat different results of these studies from several initial reports that examined melatonin rhythms in PD in 1990s (Fertl, Auff et al. 1991, Fertl, Auff et al. 1993). These recent observations will need to be better delineated in longitudinal studies employing larger cohorts of PD patients.

Strong oscillatory expression patterns of core clock genes in human blood provide an opportunity to examine circadian regulation from the molecular perspective. Several recent studies examined time-related variations in the expression of several core clock genes patients with PD. Among 17 individuals with PD and 16 age-matched controls, the relative abundance of the clock gene *Bmal1* was significantly lower during the night in PD patients. Expression levels of *Bmal1* patients correlated with PD severity as assessed by the Unified Parkinson Disease Rating Scale (UPDRS) (Cai, Liu et al. 2009). This study did not examine daytime expression of clock genes. A lack of time-dependent variation in *Bmal1* expression in PD patients was recently confirmed in another study (Breen, Vuono et al. 2014). These studies have laid out the groundwork for future clinical investigations related to molecular regulation of circadian timekeeping in PD and other neurodegenerative disorders.

Cortisol rhythm also appears to be impaired in PD. While PD patients exhibit a preserved circadian rhythm of cortisol, the amount of cortisol secreted is elevated in early PD (Breen, Vuono et al. 2014). However, somatotrophic, thyrotrophic and lactotrophic axes appear to be intact in early-stage PD (Aziz, Pijl et al. 2011). Adipokines are endocrine factors released by fat cells and have an important role in feeding, body weight regulation and metabolism. Since patients with PD frequently experience weight loss, a recent study by Aziz et al. focused on the circadian aspects of adipokines in PD, specifically leptin, adiponectin and resistin, and found no differences in the levels between PD patients and controls (Aziz, Pijl et al. 2011).

### 4.3. Circadian zeitgebers and PD

Light is the most important and potent synchronizer for the human circadian system (Czeisler, Allan et al. 1986, Klerman, Rimmer et al. 1998). Epidemiological studies suggest that higher levels of light exposure are related to a lower risk for PD. Two studies reported

increasing incidence of PD, as much as 56%, with higher latitudes, where the yearly net exposure to light is significantly lower (De Pedro Cuesta, 1987, de Pedro Cuesta and Stawiarz 1999). Activation of the SCN has been hypothesized as one of the mechanisms of bright environmental light effects on mood, sleep and circadian rhythms (McEnany and Lee 2005, Riemersma-van der Lek, Swaab et al. 2008). Supplemental exposure to bright light through light therapy (LT) in the PD population, provide an opportunity to indirectly learn about circadian function in PD. To date, several studies have been published on LT in PD (Paus, Schmitz-Hubsch et al. 2007, Willis and Turner 2007, Willis, Moore et al. 2012).

In a case series of 12 PD patients with insomnia and/or depressive symptoms, bright LT of 1000–1500 lux administered for 60–90 minutes prior to the habitual bedtime over a two-week period resulted in improved sleep onset latency, sleep continuity, and mood (Willis and Turner 2007). Beneficial effects on sleep emerged within two to three days after commencing LT, and lasted for several days after discontinuation. The antidepressant effect was longer lasting, up to several weeks after discontinuation of LT. Bright LT also resulted in improvements in bradykinesia and rigidity symptoms, which led to successful reduction of dopamine replacement therapy in half of the study cohort.

In an open label study, 120 PD patients were prescribed bright LT at the dose of 4000 to 6000 lux for 60 minutes prior to the habitual bedtime, and were followed from a few months to eight years (Willis, Moore et al. 2012). Patients with good compliance achieved improvements in mood, anxiety, and tests of motor function. Participants that quit LT early in the treatment period deteriorated over time, while those who remained semi-adherent to LT showed improvements that corresponded with periods of adherence with LT.

In the only controlled LT study in PD, 36 PD patients were randomized to receive bright LT with 7500 lux or placebo LT of 950 lux, for 30 minutes in the morning during two-week period (Paus, Schmitz-Hubsch et al. 2007). Bright LT was associated in significantly improved UPDRS part I and II scores, and modest improvements in mood and daytime sleepiness. The short duration of the study and enrollment of patients with mild depression may explain the modest effects of LT on mood. Beneficial effects of LT on sleepiness were observed in both study groups, which might represent the result of a biological placebo effect, since the intensity of the control lighting condition may have not been fully inert.

The side effect profile in these clinical PD LT studies is consistent with other light therapy studies, including transient headache, eye itching, sleepiness (Terman and Terman 1999, Terman and Terman 2005). These studies demonstrate beneficial effects of bright LT on sleep, mood and non-motor function in PD. Differences in timing of LT in studies performed to date may explain its variable effects on specific outcomes. Due to limitations of these studies, mainly their relatively small size, short duration, and suboptimal design, further studies designed to test the efficacy of LT, and its mechanisms of action, in treating motor and non-motor symptoms in patients with PD are warranted.

## 5. Future directions

Increasing evidence from basic and clinical investigations points to disruption of circadian function in PD. This is likely reflective of the neurodegenerative process of PD that affects sleep-wake regulatory centers and its connections with the circadian circuitry. Further, dopaminergic deficits that represent a neurochemical hallmark of PD, negatively affect circadian function since dopamine represents a major regulator of the circadian system.

Future research efforts in this field will need to center on the systematic study of circadian system in PD by employing longitudinal assessments and carefully designed study protocols that will allow for proper characterization of endogenous circadian signaling in the PD population. Such studies may examine the role of dopamine in the regulation of circadian system, provide the characterization of the circadian system/function from physiological, molecular and behavioral perspectives throughout the course of PD but also in pre-manifest PD, and develop circadian-based interventions for PD. Limitations of conducting such circadian studies in PD patients are substantial, given the burden of PD symptoms and frailty of PD patients. Therefore, it will be critical to establish a collaborative research programs between clinical investigators and basic/translational neuroscientists in order to advance our understanding of circadian regulation in PD through exploration of animal models of PD-relevant neurodegeneration.

As any novel research area, circadian research in PD provides very exciting and promising direction with potential to improve PD burden and better understand the biology of the disease. One of the key questions is whether there is a bi-directional relationship between PD and circadian health. Does circadian function itself affects the biology of PD? Answer to this question may position circadian system as a novel target in PD with direct potential for development of circadian based intervention for PD.

## Acknowledgments

Dr. Videnovic received research grant support from the National Institutes of Health (K23 NS072283).

## References

- Agostino PV, Do Nascimento M, Bussi IL, et al. Circadian modulation of interval timing in mice. *Brain Res.* 2011; 1370:154–163. [PubMed: 21078306]
- Agostino PV, Golombek DA, Meck WH. Unwinding the molecular basis of interval and circadian timing. *Front Integr Neurosci.* 2011; 5:64. [PubMed: 22022309]
- Alves G, Forsaa EB, Pedersen KF, et al. Epidemiology of Parkinson's disease. *J Neurol.* 2008; 255(Suppl 5):18–32. [PubMed: 18787879]
- Arias-Vera JR, Mansoor GA, White WB. Abnormalities in blood pressure regulation in a patient with Parkinson's disease. *Am J Hypertens.* 2003; 16(7):612–613. [PubMed: 12850398]
- Aziz NA, Pijl H, Frolich M, et al. Diurnal secretion profiles of growth hormone, thyrotrophin and prolactin in Parkinson's disease. *J Neuroendocrinol.* 2011; 23(6):519–524. [PubMed: 21466597]
- Aziz NA, Pijl H, Fillich M, et al. Leptin, adiponectin, and resistin secretion and diurnal rhythmicity are unaltered in Parkinson's disease. *Mov Disord.* 2011; 26(4):760–761. [PubMed: 21271615]
- Baier PC, Trenkwalder C. Circadian variation in restless legs syndrome. *Sleep Med.* 2007; 8(6):645–650. [PubMed: 17383937]

- Ben V, Bruguierolle B. Effects of bilateral striatal 6-OHDA lesions on circadian rhythms in the rat: a radiotelemetric study. *Life Sci.* 2000; 67(13):1549–1558. [PubMed: 10983850]
- Bolitho SJ, Naismith SL, Rajaratnam SM, et al. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. *Sleep Med.* 2014; 15(3):342–347. [PubMed: 24529544]
- Bonuccelli U, Del Dotto P, Lucetti C, et al. Diurnal motor variations to repeated doses of levodopa in Parkinson's disease. *Clin Neuropharmacol.* 2000; 23(1):28–33. [PubMed: 10682228]
- Boulamery A, Simon N, Vidal J, et al. Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study. *Chronobiol Int.* 2010; 27(2):251–264. [PubMed: 20370468]
- Breen DP, Vuono R, Nawarathna U, et al. Sleep and circadian rhythm regulation in early Parkinson disease. *JAMA Neurol.* 2014; 71(5):589–95. [PubMed: 24687146]
- Brown SA, Schmitt K, Eckert A. Aging and circadian disruption: causes and effects. *Aging (Albany NY).* 2011; 3(8):813–817. [PubMed: 21869460]
- Burns RS, Chiueh CC, Markey SP, et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. *Proc Natl Acad Sci U S A.* 1983; 80(14):4546–4550. [PubMed: 6192438]
- Bussi IL, Levin G, Golombek DA, et al. Involvement of dopamine signaling in the circadian modulation of interval timing. *Eur J Neurosci.* 2014; 40(1):2299–2310. [PubMed: 24689904]
- Cai Y, Liu S, Sothorn RB, et al. Expression of clock genes *Per1* and *Bmal1* in total leukocytes in health and Parkinson's disease. *Eur J Neurol.* 2010; 17(4):550–554. [PubMed: 19912323]
- Castaneda TR, de Prado BM, Prieto D, et al. Circadian rhythms of dopamine, glutamate and GABA in the striatum and nucleus accumbens of the awake rat: modulation by light. *J Pineal Res.* 2004; 36(3):177–185. [PubMed: 15009508]
- Comella CL. Sleep disorders in Parkinson's disease: An overview. *Mov Disord.* 2007; 22(S17):S367–S373. [PubMed: 18175398]
- Crabtree DM, Zhang J. Genetically engineered mouse models of Parkinson's disease. *Brain Res Bull.* 2012; 88(1):13–32. [PubMed: 21839151]
- Czeisler CA, Allan JS, Strogatz SH, et al. Bright light resets the human circadian pacemaker independent of the timing of the sleep-wake cycle. *Science.* 1986; 233(4764):667–671. [PubMed: 3726555]
- de Pedro Cuesta J. Studies on the prevalence of paralysis agitans by tracer methodology. *Acta Neurol Scand Suppl.* 1987; 112:1–106. [PubMed: 3303809]
- de Pedro-Cuesta J, Stawiarz L. Parkinson's disease incidence: magnitude, comparability, time trends. *Acta Neurol Scand.* 1991; 84(5):382–388. [PubMed: 1776385]
- Devos D, Kroumova M, Bordet R, et al. Heart rate variability and Parkinson's disease severity. *J Neural Transm.* 2003; 110(9):997–1011. [PubMed: 12928836]
- Divito CB, Steece-Collier K, Case DT, et al. Loss of VGLUT3 Produces Circadian-Dependent Hyperdopaminergia and Ameliorates Motor Dysfunction and l-Dopa-Mediated Dyskinesias in a Model of Parkinson's Disease. *J Neurosci.* 2015; 35(45):14983–14999. [PubMed: 26558771]
- Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. *Neurology.* 2007; 68(5):384–386. [PubMed: 17082464]
- Ejaz AA, Sekhon IS, Munjal S. Characteristic findings on 24-h ambulatory blood pressure monitoring in a series of patients with Parkinson's disease. *Eur J Intern Med.* 2006; 17(6):417–420. [PubMed: 16962949]
- Factor SA, Weiner WJ. 'Sleep benefit' in Parkinson's disease. *Neurology.* 1998; 50:1514e5.
- Fertl E, Auff E, Doppelbauer A, et al. Circadian secretion pattern of melatonin in Parkinson's disease. *J Neural Transm Park Dis Dement Sect.* 1991; 3(1):41–47. [PubMed: 2064730]
- Fertl E, Auff E, Doppelbauer A, et al. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. *J Neural Transm Park Dis Dement Sect.* 1993; 5(3):227–234. [PubMed: 8369102]
- Fifel K, Cooper HM. Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease. *Neurobiol Dis.* 2014; 71:359–369. [PubMed: 25171792]

- Fifel K, Piggins H, Deboer T. Modeling sleep alterations in Parkinson's disease: How close are we to valid translational animal models? *Sleep Med Rev.* 2016; 25:95–111. [PubMed: 26163055]
- Fliers E, Swaab DF, Pool CW, et al. The vasopressin and oxytocin neurons in the human supraoptic and paraventricular nucleus; changes with aging and in senile dementia. *Brain Res.* 1985; 342(1): 45–53. [PubMed: 4041817]
- Golombek DA, Bussi IL, Agostino PV. Minutes, days and years: molecular interactions among different scales of biological timing. *Philos Trans R Soc Lond B Biol Sci.* 2014; 369(1637): 20120465. [PubMed: 24446499]
- Gravotta L, Gavrilla LA, Hood S, et al. Global depletion of dopamine using intracerebroventricular 6-hydroxydopamine injection disrupts normal circadian wheel-running patterns and PERIOD2 expression in the rat forebrain. *J Mol Neurosci.* 2011; 45(2):162–171. [PubMed: 21484443]
- Haapaniemi TH, Pursiainen V, Korpelainen T, et al. Ambulatory ECG and analysis of heart rate variability in Parkinson's disease. *J Neurol Neurosurg Psychiatry.* 2001; 70(3):305–310. [PubMed: 11181850]
- Hineno T, Mizobuchi M, Hiratani K, et al. Disappearance of circadian rhythms in Parkinson's disease model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in dogs. *Brain Res.* 1992; 580(1–2):92–99. [PubMed: 1504821]
- Hogl BE, Gomez-Arevalo G, Garcia S, et al. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease. *Neurology.* 1998; 50:1332e9. [PubMed: 9595983]
- Hood S, Cassidy P, Cossette MP, et al. Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. *J Neurosci.* 2010; 30(42):14046–14058. [PubMed: 20962226]
- Hyacinthe C, Barraud Q, Bezard E, et al. D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism. *Neurobiol Dis.* 2014; 63:20–24. [PubMed: 24211719]
- Ikeda E, Matsunaga N, Kakimoto K, et al. Molecular mechanism regulating 24-hour rhythm of dopamine D3 receptor expression in mouse ventral striatum. *Mol Pharmacol.* 2013; 83(5):959–967. [PubMed: 23429911]
- Jagmag SA, Tripathi N, Shukla D, et al. Evaluation of Models of Parkinson's Disease. *Front Neurosci.* 2015; 9:503. [PubMed: 26834536]
- Johnston TM, Fox SH, et al. Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates. *Curr Top Behav Neurosci.* 2015; 22:221–235. [PubMed: 25158623]
- Ju YE, Lucey BP, Holtzman DM, et al. Sleep and Alzheimer disease pathology--a bidirectional relationship. *Nat Rev Neurol.* 2014; 10(2):115–119. [PubMed: 24366271]
- Kafka MS, Benedito MA, Roth RH, et al. Circadian rhythms in catecholamine metabolites and cyclic nucleotide production. *Chronobiol Int.* 1986; 3(2):101–115. [PubMed: 2824067]
- Kallio M, Haapaniemi T, Turkka J, et al. Heart rate variability in patients with untreated Parkinson's disease. *Eur J Neurol.* 2000; 7(6):667–672. [PubMed: 11136353]
- Kallio M, Suominen K, Haapaniemi T, et al. Nocturnal cardiac autonomic regulation in Parkinson's disease. *Clin Auton Res.* 2004; 14(2):119–124. [PubMed: 15095055]
- Klerman EB, Rimmer DW, DJ, et al. Nonphotic entrainment of the human circadian pacemaker. *Am J Physiol.* 1998; 274(4 Pt 2):R991–996. [PubMed: 9575961]
- Kudo T, Loh DH, Truong D, et al. Circadian dysfunction in a mouse model of Parkinson's disease. *Exp Neurol.* 2011; 232(1):66–75. [PubMed: 21864527]
- Laloux C, Derambure P, Houdayer E, et al. Effect of dopaminergic substances on sleep/wakefulness in saline- and MPTP-treated mice. *J Sleep Res.* 2008; 17(1):101–110. [PubMed: 18275560]
- Li SX, Liu LJ, Jiang WG, et al. Morphine withdrawal produces circadian rhythm alterations of clock genes in mesolimbic brain areas and peripheral blood mononuclear cells in rats. *J Neurochem.* 2009; 109(6):1668–1679. [PubMed: 19383088]
- Mamelak M. Neurodegeneration, sleep, and cerebral energy metabolism: a testable hypothesis. *J Geriatr Psychiatry Neurol.* 1997; 10(1):29–32. [PubMed: 9100156]
- Mastrocola C, Vanacore N, Giovani A, et al. Twenty-four-hour heart rate variability to assess autonomic function in Parkinson's disease. *Acta Neurol Scand.* 1999; 99(4):245–247. [PubMed: 10225356]

- Mattam U, Jagota A. Daily rhythms of serotonin metabolism and the expression of clock genes in suprachiasmatic nucleus of rotenone-induced Parkinson's disease male Wistar rat model and effect of melatonin administration. *Biogerontology*. 2015; 16(1):109–123. [PubMed: 25430725]
- Mattis J, Sehgal A. Circadian Rhythms, Sleep, and Disorders of Aging. *Trends Endocrinol Metab*. 2016; 27(4):192–203. [PubMed: 26947521]
- McDowell K, Chesselet MF. Animal models of the non-motor features of Parkinson's disease. *Neurobiol Dis*. 2012; 46(3):597–606. [PubMed: 22236386]
- McDowell KA, Shin D, Roos KP, et al. Sleep dysfunction and EEG alterations in mice overexpressing alpha-synuclein. *J Parkinsons Dis*. 2014; 4(3):531–539. [PubMed: 24867919]
- McEnany GW, Lee KA. Effects of light therapy on sleep, mood, and temperature in women with nonseasonal major depression. *Issues Ment Health Nurs*. 2005; 26(7):781–794. [PubMed: 16126652]
- Mendoza J, Challet E. Circadian insights into dopamine mechanisms. *Neuroscience*. 2014; 282:230–242. [PubMed: 25281877]
- Merello M, Hughes A, Colosimo C, et al. Sleep benefit in Parkinson's disease. *Mov Disord*. 1997; 12:506e8. [PubMed: 9251067]
- Mihci E, Kardelen F, Dora B, et al. Orthostatic heart rate variability analysis in idiopathic Parkinson's disease. *Acta Neurol Scand*. 2006; 113(5):288–293. [PubMed: 16629763]
- Morton AJ, Wood NI, Hastings MH, et al. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. *J Neurosci*. 2005; 25(1):157–163. [PubMed: 15634777]
- Natsubori A, Honma K, Honma S. Dual regulation of clock gene *Per2* expression in discrete brain areas by the circadian pacemaker and methamphetamine-induced oscillator in rats. *Eur J Neurosci*. 2014; 39(2):229–240. [PubMed: 24438490]
- Nutt JG, Woodward WE, Carter JH, et al. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. *J Neurol Neurosurg Psychiatry*. 1989; 52(4):481–487. [PubMed: 2738591]
- Parekh PK, Ozburn AR, McClung CA. Circadian clock genes: effects on dopamine, reward and addiction. *Alcohol*. 2015; 49(4):341–349. [PubMed: 25641765]
- Pathak A, Senard JM. Blood pressure disorders during Parkinson's disease: epidemiology, pathophysiology and management. *Expert Rev Neurother*. 2006; 6(8):1173–1180. [PubMed: 16893345]
- Paus S, Schmitz-Hubsch T, Wullner M, et al. Bright light therapy in Parkinson's disease: a pilot study. *Mov Disord*. 2007; 22(10):1495–1498. [PubMed: 17516492]
- Piccini P, Del Dotto P, Pardini C, et al. Diurnal worsening in Parkinson patients treated with levodopa. *Riv Neurol*. 1991; 61(6):219–224. [PubMed: 1813974]
- Placidi F, Izzi F, Romigi A, et al. Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study. *J Neurol*. 2008; 255(7):1032–1037. [PubMed: 18500498]
- Poceta JS, Parsons L, Engelland S, et al. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. *Sleep Med*. 2009; 10(1):129–133. [PubMed: 18207455]
- Porter B, Macfarlane R, Walker R. The frequency and nature of sleep disorders in a community-based population of patients with Parkinson's disease. *Eur J Neurol*. 2008; 15(1):50–54. [PubMed: 18042241]
- Pungor K, Papp M, Kekesi K, et al. A novel effect of MPTP: the selective suppression of paradoxical sleep in cats. *Brain Res*. 1990; 525(2):310–314. [PubMed: 2253031]
- Pursiainen V, Haapaniemi TH, Korpelainen JT, et al. Circadian heart rate variability in Parkinson's disease. *J Neurol*. 2002; 249(11):1535–1540. [PubMed: 12420094]
- Riemersma-van der Lek RF, Swaab DF, Twisk J, et al. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. *Jama*. 2008; 299(22):2642–2655. [PubMed: 18544724]
- Roybal K, Theobald D, Graham A, et al. Mania-like behavior induced by disruption of *CLOCK*. *Proc Natl Acad Sci U S A*. 2007; 104:6406–6411. [PubMed: 17379666]

- Seron-Ferre M, Torres-Farfan C, Forcelledo ML, et al. The development of circadian rhythms in the fetus and neonate. *Semin Perinatol.* 2001; 25(6):363–370. [PubMed: 11778907]
- Shumay E, Fowler JS, Wang GJ, et al. Repeat variation in the human PER2 gene as a new genetic marker associated with cocaine addiction and brain dopamine D2 receptor availability. *Transl Psychiatry.* 2012; 2:e86. [PubMed: 22832851]
- Sleipness EP, Sorg BA, Jansen HT. Diurnal differences in dopamine transporter and tyrosine hydroxylase levels in rat brain: dependence on the suprachiasmatic nucleus. *Brain Res.* 2007; 1129(1):34–42. [PubMed: 17156761]
- Struck LK, Rodnitzky RL, Dobson JK. Circadian fluctuations of contrast sensitivity in Parkinson's disease. *Neurology.* 1990; 40(3 Pt 1):467–470. [PubMed: 2314590]
- Suzuki K, Miyamoto T, Miyamoto M, et al. Circadian variation of core body temperature in Parkinson disease patients with depression: a potential biological marker for depression in Parkinson disease. *Neuropsychobiology.* 2007; 56(4):172–179. [PubMed: 18332645]
- Taylor TN, Caudle WM, Shepherd KR, et al. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. *J Neurosci.* 2009; 29(25):8103–8113. [PubMed: 19553450]
- Terman M, Terman JS. Bright light therapy: side effects and benefits across the symptom spectrum. *J Clin Psychiatry.* 1999; 60(11):799–808. [PubMed: 10584776]
- Terman M, Terman JS. Light therapy for seasonal and nonseasonal depression: efficacy, protocol, safety, and side effects. *CNS Spectr.* 2005; 10(8):647–663. [PubMed: 16041296]
- van Hilten B, Hoff JJ, Middelkoop HA, et al. Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring. *Arch Neurol.* 1994; 51(9):922–928. [PubMed: 8080393]
- van Hilten JJ, Hoogland G, van der Velde EA, et al. Diurnal effects of motor activity and fatigue in Parkinson's disease. *J Neurol Neurosurg Psychiatry.* 1993; 56(8):874–877. [PubMed: 8350103]
- van Hilten JJ, Kabel JF, Middelkoop HA, et al. Assessment of response fluctuations in Parkinson's disease by ambulatory wrist activity monitoring. *Acta Neurol Scand.* 1993; 87(3):171–177. [PubMed: 8475685]
- van Hilten JJ, Middelkoop HA, Kerkhof GA, et al. A new approach in the assessment of motor activity in Parkinson's disease. *J Neurol Neurosurg Psychiatry.* 1991; 54(11):976–979. [PubMed: 1800670]
- van Hilten JJ, Weggeman M, van der Velde EA, et al. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. *J Neural Transm Park Dis Dement Sect.* 1993; 5(3):235–244. [PubMed: 8369103]
- van Gilst MM, Bloem BR, Overeem S. "Sleep benefit" in Parkinson's disease: a systematic review. *Parkinsonism Relat Disord.* 2013; 19(7):654–659. [PubMed: 23615667]
- Verbaan D, van Rooden SM, Visser M, et al. Nighttime sleep problems and daytime sleepiness in Parkinson's disease. *Mov Disord.* 2008; 23(1):35–41. [PubMed: 17960797]
- Vezoli J, Fifel K, Leviel V, et al. Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson's disease. *PLoS One.* 2011; 6(8):e2395p42.
- Videnovic A, Golombek D. Circadian and sleep disorders in Parkinson's disease. *Exp Neurol.* 2013; 24:45–56.
- Videnovic A, Lazar AS, Barker RA, et al. "The clock that time us" - circadian rhythms in neurodegenerative disorders. *Nat Rev Neurol.* 2014; 10(12):683–693. [PubMed: 25385339]
- Videnovic A, Noble C, Reid KJ, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. *JAMA Neurol.* 2014; 71(4):463–469. [PubMed: 24566763]
- Videnovic A, Willis GL. Circadian system - A novel diagnostic and therapeutic target in Parkinson's disease? *Mov Disord.* 2016; 31(3):260–269. [PubMed: 26826022]
- Whitehead DL, Davies AD, Playfer JR, et al. Circadian rest-activity rhythm is altered in Parkinson's disease patients with hallucinations. *Mov Disord.* 2008; 23(8):1137–1145. [PubMed: 18442142]
- Willis GL, Kelly AM, Kennedy GA. Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model. *Behav Brain Res.* 2008; 193(1):37–47. [PubMed: 18547659]

- Willis GL, Turner EJ. Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study. *Chronobiol Int.* 2007; 24(3):521–537. [PubMed: 17612949]
- Willis GL, Moore C, Armstrong SM. A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson's disease. *Rev Neurosci.* 2012; 23(2):199–226. [PubMed: 22499678]
- Willison LD, Kudo T, Loh DH, et al. Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model. *Exp Neurol.* 2013; 243:57–66. [PubMed: 23353924]
- Witkovsky P. Dopamine and retinal function. *Doc Ophthalmol.* 2004; 108(1):17–40. [PubMed: 15104164]
- Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. *Cell Mol Neurobiol.* 2001; 21(6):605–616. [PubMed: 12043836]